{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:40:07Z","timestamp":1790635207461,"version":"4.1.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Gonadotropin-releasing hormone agonists (GnRHa's) are the standard treatment for children with central precocious puberty (CPP). We aim to present data on available GnRHa options with an easy-to-review table and discuss factors that influence treatment selection. Five GnRHa's are currently FDA-approved and prescribed in the US and published data suggest similar safety and efficacy profiles over the first year of treatment. One- and 3-month intramuscular (IM) leuprolide acetate (LA) have long-term safety and efficacy data and allow for flexible dosing. Six-month IM triptorelin pamoate offers a longer duration of treatment, but without long-term efficacy and outcome data. Six-month subcutaneous (SQ) LA combines a SQ route of injection and long duration of action but lacks long-term efficacy and outcome data. The 12-month SQ histrelin acetate implant avoids injections and offers the longest duration of action, but requires a minor surgical procedure with local or general anesthesia. Factors in treatment selection include route of administration, needle size, injection volume, duration of action, and cost. The current GnRHa landscape provides options with varying benefits and risks, allowing physicians and caregivers to select the most appropriate therapy based on the specific needs and concerns of the child and the caregiver. Agents have different advantages and disadvantages for use, with no one agent displaying superiority.<\/jats:p>","DOI":"10.3389\/fped.2022.968485","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T07:27:38Z","timestamp":1664868458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States"],"prefix":"10.3389","volume":"10","author":[{"given":"Jadranka","family":"Popovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Geffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Rogol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Kaplowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Mauras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Zeitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Eugster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen O.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"B1","article-title":"National Institute of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development","year":"2016"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1210\/jc.2013-1024","article-title":"Treatment and outcomes of precocious puberty: an update","volume":"98","author":"Fuqua","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000185432","article-title":"Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or Gnrh analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method","volume":"47","author":"Kauli","year":"1997","journal-title":"Horm Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1210\/jc.2007-1216","article-title":"Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function","volume":"93","author":"Pasquino","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/adc.81.4.329","article-title":"Randomised trial of Lhrh analogue treatment on final height in girls with onset of puberty aged 75-85 years","volume":"81","author":"Cassio","year":"1999","journal-title":"Arch Dis Child."},{"key":"B6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/00148581-200406040-00002","article-title":"Central precocious puberty: current treatment options","volume":"6","author":"Antoniazzi","year":"2004","journal-title":"Paediatr Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1037\/a0024008","article-title":"Elevated social anxiety among early maturing girls","volume":"47","author":"Blumenthal","year":"2011","journal-title":"Dev Psychol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics."},{"key":"B9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jadohealth.2012.12.018","article-title":"Early puberty and childhood social and behavioral adjustment","volume":"53","author":"Mensah","year":"2013","journal-title":"J Adolesc Health."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e20171703","DOI":"10.1542\/peds.2017-1703","article-title":"Age at menarche, depression, and antisocial behavior in adulthood","volume":"141","author":"Mendle","year":"2018","journal-title":"Pediatrics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/03007995.2019.1699517","article-title":"A survey of care pathway and health-related quality of life impact for children with central precocious puberty","volume":"36","author":"Klein","year":"2020","journal-title":"Curr Med Res Opin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12955-021-01805-w","article-title":"The Association between family impact and health-related quality of life of children with idiopathic central precocious puberty in Chongqing, China","volume":"19","author":"Yang","year":"2021","journal-title":"Health Qual Life Outcomes."},{"key":"B13","article-title":"AbbVie Inc","year":"1993","journal-title":"Lupron Depot-Ped"},{"key":"B14","volume-title":"Lupron Depot (Leuprolide Acetate for Depot Suspension) [Prescription Information]","year":"2011"},{"key":"B15","year":"2017","journal-title":"Triptodur"},{"key":"B16","article-title":"Tolmar Pharmaceuticals, Inc","year":"2020","journal-title":"Fensolvi"},{"key":"B17","article-title":"Endo Pharmaceuticals Inc","year":"2011","journal-title":"Supprelin"},{"key":"B18","year":"1998","journal-title":"Synarel"},{"key":"B19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000501336","article-title":"Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium","volume":"91","author":"Bangalore Krishna","year":"2019","journal-title":"Horm Res Paediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0201906","DOI":"10.1371\/journal.pone.0201906","article-title":"Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE."},{"key":"B21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1477-7525-3-34","article-title":"Health-related quality of life measurement in pediatric clinical practice: an appraisal and precept for future research and application","volume":"3","author":"Varni","year":"2005","journal-title":"Health Qual Life Outcomes."},{"key":"B22","doi-asserted-by":"publisher","first-page":"398639","DOI":"10.1186\/1687-9856-2010-398639","article-title":"Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery","volume":"2010","author":"Neely","year":"2010","journal-title":"Int J Pediatr Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1687-9856-2011-7","article-title":"Efficacy of leuprolide acetate 1-month depot for central precocious puberty (Cpp): growth outcomes during a prospective, longitudinal study","volume":"2011","author":"Lee","year":"2011","journal-title":"Int J Pediatr Endocrinol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1210\/jc.2011-2704","article-title":"Efficacy and safety of leuprolide acetate 3-month Depot 1125 milligrams or 30 milligrams for the treatment of central precocious puberty","volume":"97","author":"Lee","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B25","unstructured":"Histrelin Subcutaneous Implant in Children With Central Precocious Puberty2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1515\/jpem-2015-0376","article-title":"Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty","volume":"29","author":"Klein","year":"2016","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e3660","DOI":"10.1210\/clinem\/dgaa479","article-title":"Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty","volume":"105","author":"Klein","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1210\/jc.2014-3031","article-title":"Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial","volume":"100","author":"Silverman","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B29","volume-title":"WHO International Collaborative Study of the Proposed 5th International Standard for Human, Urinary Follicle-Stimulating Hormone and Human, Urinary Luteinizing Hormone, for Bioassay","author":"Ferguson","year":"2012"},{"key":"B30","volume-title":"WHO International Collaborative Study of the Proposed 3rd International Standard for Human, Pituitary Luteinizing Hormone","author":"Ferguson","year":"2014"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1210\/jcem.83.7.4929","article-title":"Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist","volume":"83","author":"Klein","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"B32","volume-title":"Data From: A Review of Current Therapies for Children with Central Precocious Puberty. Different International Unit Versions Are Not Comparable.","author":"Popovic","year":"2022"},{"key":"B33","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1515\/jpem-2021-0114","article-title":"Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years","volume":"34","author":"Vargas Trujillo","year":"2021","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1210\/jc.2013-4471","article-title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty","volume":"99","author":"Lee","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1210\/jc.2006-2479","article-title":"Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial","volume":"92","author":"Eugster","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1687-9856-2013-20","article-title":"Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy","volume":"2013","author":"Neely","year":"2013","journal-title":"Int J Pediatr Endocrinol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1542\/peds.2005-0538","article-title":"The histrelin implant: a novel treatment for central precocious puberty","volume":"116","author":"Hirsch","year":"2005","journal-title":"Pediatrics."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jpeds.2013.05.033","article-title":"Single histrelin implant is effective for 2 years for treatment of central precocious puberty","volume":"163","author":"Lewis","year":"2013","journal-title":"J Pediatr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0169-409X(97)00050-1","article-title":"One- and three-month release injectable microspheres of the Lh-Rh superagonist leuprorelin acetate","volume":"28","author":"Okada","year":"1997","journal-title":"Adv Drug Deliv Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1023\/A:1018936815654","article-title":"Preparation of rhree-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers","volume":"11","author":"Okada","year":"1994","journal-title":"Pharm Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.46624\/ajptr.2019.v9.i2.013","article-title":"Atrigel-implants and controlled release drug delivery system: a review","volume":"9","author":"Thakare","year":"2019","journal-title":"Am J PharmTech Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.epsc.2015.10.001","article-title":"Severe allergic reaction following histrelin implant (supprelin la)","volume":"3","author":"Donnelly","year":"2015","journal-title":"JPS Case Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000439330","article-title":"Experience with the histrelin implant in pediatric patients","volume":"30","author":"Eugster","year":"2016","journal-title":"Endocr Dev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.jpedsurg.2018.08.048","article-title":"Histrelin implantation in the pediatric population: a 10-year institutional experience","volume":"54","author":"Swendiman","year":"2019","journal-title":"J Pediatr Surg."},{"key":"B45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1515\/jpem.2011.432","article-title":"Intraoperative sonographic localization of a fractured supprelin implant in a pediatric patient: a case report","volume":"25","author":"Monroe","year":"2012","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jpedsurg.2014.02.067","article-title":"Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty","volume":"49","author":"Davis","year":"2014","journal-title":"J Pediatr Surg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"812517","DOI":"10.1186\/1687-9856-2009-812517","article-title":"Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty","volume":"2009","author":"Rahhal","year":"2009","journal-title":"Int J Pediatr Endocrinol."},{"key":"B48","first-page":"1","article-title":"Partially retained supprelin implant leads to continuous pubertal supression","volume":"93","author":"Silverman","year":"2020","journal-title":"Horm Res Paediatr."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SAT-298","article-title":"Sat-298 a case of a forgotten histrelin acetate implant: can histrelin acetate implants be used for more than a year?","volume":"3","author":"Krishnaraj","year":"2019","journal-title":"J Endocr Soc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"bvab189","DOI":"10.1210\/jendso\/bvab189","article-title":"Gonadotropin suppression for 7 years after a single histrelin implant for precocious puberty","volume":"6","author":"Villalta","year":"2022","journal-title":"J Endocr Soc."},{"key":"B51","doi-asserted-by":"publisher","first-page":"135","DOI":"10.6065\/apem.2014.19.3.135","article-title":"Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty","volume":"19","author":"Lee","year":"2014","journal-title":"Ann Pediatr Endocrinol Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.clinthera.2010.09.009","article-title":"Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists","volume":"32","author":"Miller","year":"2010","journal-title":"Clin Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"E136","DOI":"10.1111\/j.1440-1754.2011.02083.x","article-title":"Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty","volume":"48","author":"Johnson","year":"2012","journal-title":"J Paediatr Child Health."},{"key":"B54","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0022-3476(95)70534-1","article-title":"Local reactions to luteinizing hormone releasing hormone analog therapy","volume":"126","author":"Tonini","year":"1995","journal-title":"J Pediatr."},{"key":"B55","first-page":"185","article-title":"Intramuscular injections: a review of nursing practices for adults. All Ireland","volume":"1","author":"McGarvey","year":"2001","journal-title":"J Nurs Midwifery."},{"key":"B56","volume-title":"A Nursing Perspective: Best Practices for Pubertal Suppression for Individuals with Central Precocious Puberty and Transgender","author":"Kirouac","year":"2016"},{"key":"B57","author":"Perry","year":"2017","journal-title":"Clinical Nursing Skills and Techniques."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1210\/jc.84.12.4536","article-title":"A Single sample subcutaneous luteinizing hormone (Lh)-releasing hormone (Lhrh) stimulation test for monitoring Lh suppression in children with central precocious puberty receiving Lhrh agonists","volume":"84","author":"Lawson","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"B59","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/pde.13739","article-title":"Use of psychologic strategies to reduce pain and anxiety related to dermatology procedures","volume":"36","author":"Armenta","year":"2019","journal-title":"Pediatr Dermatol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1097\/AJP.0000000000000273","article-title":"Interventions for individuals with high levels of needle fear: systematic review of randomized controlled trials and quasi-randomized controlled trials","volume":"31","author":"McMurtry","year":"2015","journal-title":"Clin J Pain."},{"key":"B61","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1089\/dia.2012.0334","article-title":"Comparison between shorter straight and thinner microtapered insulin injection needles","volume":"15","author":"Nagai","year":"2013","journal-title":"Diabetes Technol Ther."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.clinthera.2004.10.007","article-title":"A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge X 6 Mm Needle Versus a 29 Gauge X 127 Mm needle in obese patients with diabetes mellitus","volume":"26","author":"Schwartz","year":"2004","journal-title":"Clin Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/193229680700100516","article-title":"Comparison of patient's preference, pain perception, and usability between micro fine plus 31-gauge needle and microtapered nanopass 33-gauge needle for insulin therapy","volume":"1","author":"Miyakoshi","year":"2007","journal-title":"J Diabetes Sci Technol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/08990220600700925","article-title":"Pain following controlled cutaneous insertion of needles with different diameters","volume":"23","author":"Arendt-Nielsen","year":"2006","journal-title":"Somatosens Mot Res."},{"key":"B65","article-title":"Centers for Disease Control and Prevention","year":"2020"},{"key":"B66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.7257\/1053-816X.2019.39.2.83","article-title":"Personalizing treatment in the delivery of care by nurses to patients with prostate cancer","volume":"39","author":"Prettyman J","year":"2019","journal-title":"J Urol Nursing."},{"key":"B67","first-page":"374","article-title":"Medication Administration: Intramuscular","volume-title":"Pediatric Nursing Procedures","author":"Bowden","year":"2003"},{"key":"B68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1932296817735121","article-title":"Impact of injection speed, volume, and site on pain sensation","volume":"12","author":"Zijlstra","year":"2018","journal-title":"J Diabetes Sci Technol."},{"key":"B69","article-title":"Adherence to Monthly Injectable Leuprolide Acetate among Florida Medicaid-Enrolled Children with Central Precocious Puberty","volume-title":"42nd Midyear Clinical Meeting of the American Society of Health-System Pharamacists","author":"Hankin","year":"2007"},{"key":"B70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5409\/wjcp.v5.i2.143","article-title":"Minimizing pediatric healthcare-induced anxiety and trauma","volume":"5","author":"Lerwick","year":"2016","journal-title":"World J Clin Pediatr."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1515\/JPEM.2007.20.11.1189","article-title":"Luteinizing hormone (Lh) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection Lh levels useful in monitoring treatment?","volume":"20","author":"Kunz","year":"2007","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e20153732","DOI":"10.1542\/peds.2015-3732","article-title":"Evaluation and referral of children with signs of early puberty","volume":"137","author":"Kaplowitz","year":"2016","journal-title":"Pediatrics."},{"key":"B73","doi-asserted-by":"publisher","first-page":"298","DOI":"10.17458\/per.vol15.2018.kl.GnRHaforCPP","article-title":"Gonadotropin-releasing hormone (Gnrha) therapy for central precocious puberty (Cpp): review of nuances in assessment of height, hormonal suppression, psychosocial issues, and weight gain, with patient examples","volume":"15","author":"Klein","year":"2018","journal-title":"Pediatr Endocrinol Rev."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1210\/jc.85.3.1074","article-title":"Diurnal rhythms of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol secretion before the onset of female puberty in short children*","volume":"85","author":"Mitamura","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1210\/jcem.84.6.5647","article-title":"Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French Study Group of Decapeptyl in Precocious Puberty","volume":"84","author":"Carel","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1507\/endocrj.45.351","article-title":"Timing for discontinuation of treatment with a long-acting gonadotropin-releasing hormone analog in girls with central precocious puberty. Tap-144sr Cpp Study Group","volume":"45","author":"Ohyama","year":"1998","journal-title":"Endocr J."},{"key":"B77","doi-asserted-by":"publisher","first-page":"836","DOI":"10.18553\/jmcp.2019.25.7.836","article-title":"Health care utilization and economic burden in patients with central precocious puberty: an assessment of the commercially insured and medicaid populations","volume":"25","author":"Klein","year":"2019","journal-title":"J Manag Care Spec Pharm."},{"key":"B78","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00006250-200103000-00003","article-title":"Body fat distribution and body composition during Gnrh agonist therapy","volume":"97","author":"Yamasaki","year":"2001","journal-title":"Obstet Gynecol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40272-015-0130-8","article-title":"Central precocious puberty: update on diagnosis and treatment","volume":"17","author":"Chen","year":"2015","journal-title":"Paediatr Drugs."},{"key":"B80","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1159\/000513702","article-title":"Fertility of women treated during childhood with triptorelin (Depot formulation) for central precocious puberty: the prefer study","volume":"93","author":"Martinerie","year":"2020","journal-title":"Horm Res Paediatr."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1210\/jc.2004-1863","article-title":"Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The Tap-144-Sr Japanese Study Group on Central Precocious Puberty","volume":"90","author":"Tanaka","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"key":"B82","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s004310051289","article-title":"Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues","volume":"159","author":"Bertelloni","year":"2000","journal-title":"Eur J Pediatr."},{"key":"B83","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1210\/jcem.87.2.8202","article-title":"Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of Gnrh agonist therapy","volume":"87","author":"van der Sluis","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"key":"B84","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1515\/JPEM.2003.16.3.407","article-title":"Effects on bone mineral density of gonadotropin releasing hormone analogs used in the treatment of central precocious puberty","volume":"16","author":"Unal","year":"2003","journal-title":"J Pediatr Endocrinol Metab."},{"key":"B85","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.mce.2006.04.012","article-title":"Long-term Gnrh agonist treatment for female central precocious puberty does not impair reproductive function","volume":"55","author":"Heger","year":"2006","journal-title":"Mol Cell Endocrinol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1210\/jc.2014-3748","article-title":"Treated and untreated women with idiopathic precocious puberty: Bmi evolution, metabolic outcome, and general health between third and fifth decades","volume":"100","author":"Lazar","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","article-title":"Menarche, menopause, and BREAST cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies","volume":"13","year":"2012","journal-title":"Lancet Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13058-020-01326-2","article-title":"Pubertal timing and breast cancer risk in the sister study cohort","volume":"22","author":"Goldberg","year":"2020","journal-title":"Breast Cancer Research."},{"key":"B89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10578-004-3489-2","article-title":"Precocious puberty in adolescent girls: a biomarker of later psychosocial adjustment problems","volume":"36","author":"Tremblay","year":"2005","journal-title":"Child Psychiatry Hum Dev."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fpsyg.2016.01053","article-title":"Cognitive, emotional, and psychosocial functioning of girls treated with pharmacological puberty blockage for idiopathic central precocious puberty","volume":"7","author":"Wojniusz","year":"2016","journal-title":"Front Psychol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.968485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T07:28:02Z","timestamp":1664868482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.968485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":90,"alternative-id":["10.3389\/fped.2022.968485"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.968485","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"article-number":"968485"}}